GLP-1 Medications: Beyond Weight Loss, Toward Metabolic Health

The GLP-1 (and GLP-1/GIP) class — semaglutide, tirzepatide, and now retatrutide — is the largest pharmacologic shift in metabolic medicine in a generation. The weight-loss results are unprecedented for a non-surgical intervention. They have also produced a wave of misuse, complications, and oversimplification that deserves clear-eyed treatment.

What these drugs do

GLP-1 receptor agonists mimic glucagon-like peptide-1, an incretin hormone normally released after meals. They:

• Slow gastric emptying (so food sits in the stomach longer, blunting hunger)
• Increase insulin release in response to glucose
• Reduce glucagon release (lowers fasting glucose)
• Act centrally to reduce appetite and "food noise"

Tirzepatide adds GIP receptor agonism, producing larger weight-loss effects. Retatrutide goes further, adding glucagon receptor agonism — a triple-agonist with the largest weight-loss results in trials to date.

The weight-loss results are real

Average weight loss across the major trials:

• Semaglutide 2.4 mg: ~15% of body weight at 68 weeks
• Tirzepatide 15 mg: ~21% of body weight at 72 weeks
• Retatrutide (highest dose, in trial): ~24% of body weight at 48 weeks

For comparison, gastric bypass typically produces 25–35% weight loss. The pharmacologic options are now in a similar range — without surgery.

The cardiovascular and metabolic upside

The benefit is bigger than just weight. Trials in patients with cardiovascular disease or type 2 diabetes show:

• Reduced major adverse cardiovascular events
• Improved HbA1c, fasting insulin, and triglycerides
• Reductions in apolipoprotein B (the actual driver of cardiovascular risk)
• Improvements in NAFLD/MASH (fatty liver) markers
• Early signal for kidney protection

For the metabolically dysregulated patient, this is among the most powerful single interventions currently available.

The trade-offs everyone should know about

Muscle loss. Roughly 25–40% of total weight lost on GLP-1 monotherapy is lean mass — meaning, muscle. This is not a bug; it's what you'd expect from any rapid weight-loss intervention. The clinical implication: patients lose substantial muscle they may not get back, particularly older adults, and this matters for long-term mobility, metabolic health, and aging trajectory.

Mitigation: resistance training (real resistance training, not occasional walks), aggressive protein intake (≥1 g per pound of goal body weight), and slow, intentional dose titration rather than racing to the highest tolerated dose.

GI side effects. Nausea, constipation, occasional vomiting. Usually transient and dose-dependent. Sometimes a deal-breaker.

Gallbladder disease. Rapid weight loss in general — and these drugs specifically — increase gallstone risk.

Bone density. Less studied, but follows the same logic as any rapid weight loss: risk for accelerated bone loss, particularly in postmenopausal women.

What happens when you stop. The STEP-4 data is unambiguous: weight regain is the rule when GLP-1 therapy is discontinued. Most of the weight comes back within a year. This is a long-term medication for most people, not a short course.

Compounded vs. brand

The shortage years brought a wave of compounded semaglutide and tirzepatide into the market. Some of it was sourced and dispensed responsibly through legitimate compounding pharmacies. Some was research-chemical-grade material sold by telehealth-adjacent operators with minimal oversight. Quality varies enormously.

If a patient is going to use compounded peptides at all, they should be sourced from a reputable 503A or 503B compounding pharmacy under a real prescription, with transparent supply chain and certificates of analysis. The brand drugs (Ozempic, Wegovy, Mounjaro, Zepbound) are also options when they're available.

How we use them

GLP-1 therapy at TWW is a clinical decision, not a sale. We evaluate:

• Body composition (visceral fat, SMM trend)
• Metabolic markers (fasting insulin, HOMA-IR, ApoB, hsCRP)
• Goals (medical weight loss, body recomposition, metabolic optimization)
• Training history and what we can build alongside
• Long-term plan (how do we hand this off, how do we step down, what does maintenance look like)

We dose conservatively, monitor labs and lean mass, build the resistance-training and protein side aggressively, and we are honest with patients that this is not a short-term protocol for most.

The summary

GLP-1 medications, used responsibly, are among the most powerful metabolic-medicine tools available. They are also routinely misused — too fast, too high a dose, no resistance training, no protein, no monitoring, expectation of a 12-week intervention — and that misuse produces patients who are smaller, weaker, more sarcopenic, and back where they started 18 months later. The drug isn't the problem. The execution is.